Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeting CD20 in melanoma patients at high risk of disease recurrence.

Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W, Brunner P, Grabmeier-Pfistershammer K, Gschaider M, Lai CY, Hsu MY, Herlyn M, Stingl G, Wagner SN.

Mol Ther. 2012 May;20(5):1056-62. doi: 10.1038/mt.2012.27. Epub 2012 Feb 21.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma.

Avilés A, Talavera A, Díaz-Maqueo JC, García EL, Cleto S, Neri N.

Cancer Biother Radiopharm. 2001 Apr;16(2):159-62.

PMID:
11385962
4.

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.

Hohloch K, Sahlmann CO, Lakhani VJ, Wulf G, Glass B, Hasenkamp J, Meller J, Riggert J, Trümper L, Griesinger F.

Ann Hematol. 2011 Nov;90(11):1307-15. doi: 10.1007/s00277-011-1199-y. Epub 2011 Mar 1.

PMID:
21360108
5.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Coiffier B, Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators..

Lancet Oncol. 2011 Aug;12(8):773-84. doi: 10.1016/S1470-2045(11)70150-4. Epub 2011 Jul 1.

PMID:
21724462
6.

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.

Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Milpied NJ, Radford J, Ketterer N, Shpilberg O, Dührsen U, Hagberg H, Ma DD, Viardot A, Lowenthal R, Brière J, Salles G, Moskowitz CH, Glass B.

J Clin Oncol. 2012 Dec 20;30(36):4462-9. doi: 10.1200/JCO.2012.41.9416. Epub 2012 Oct 22.

7.

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.

Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S; 415 study investigators..

Br J Haematol. 2013 Nov;163(3):334-42. doi: 10.1111/bjh.12537. Epub 2013 Aug 23. Erratum in: Br J Haematol. 2014 May;165(3):422. Verhoef, Gregor [added].

PMID:
24032456
8.

High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.

Behr TM, Griesinger F, Riggert J, Gratz S, Béhé M, Kaufmann CC, Wörmann B, Brittinger G, Becker W.

Cancer. 2002 Feb 15;94(4 Suppl):1363-72. Erratum in: Cancer. 2005 Dec 15;104(12):2888.

9.

[Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].

Kriachok IA, Filonenko KS, Gubareva GO, Tytorenko IB, Novosad OI, Kadnikova TV, Aleksik OM, Martynchyk AV, Kushchevyĭ ÉV, Pastushenko IaV, Kutsenko LB.

Lik Sprava. 2011 Jan-Mar;(1-2):117-21. Ukrainian.

PMID:
21954645
10.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.

Lancet Oncol. 2014 Aug;15(9):1019-26. doi: 10.1016/S1470-2045(14)70311-0. Epub 2014 Jul 17.

PMID:
25042202
11.

In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia.

Berkahn L, Simpson D, Raptis A, Klingemann HG.

J Hematother Stem Cell Res. 2002 Apr;11(2):315-20.

PMID:
11983102
12.

Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.

Zent CS, Taylor RP, Lindorfer MA, Beum PV, LaPlant B, Wu W, Call TG, Bowen DA, Conte MJ, Frederick LA, Link BK, Blackwell SE, Veeramani S, Baig NA, Viswanatha DS, Weiner GJ, Witzig TE.

Am J Hematol. 2014 Jul;89(7):757-65. doi: 10.1002/ajh.23737. Epub 2014 Apr 26.

13.
14.

Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.

Laurenti L, De Padua L, Battendieri R, Tarnani M, Sica S, Blasi MA, Savino G, Leone G.

Leuk Res. 2011 May;35(5):682-4. doi: 10.1016/j.leukres.2011.01.030. Epub 2011 Feb 18.

PMID:
21334067
15.

Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.

Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, Peschel C, von Schilling C, Scheidhauer K, Keller U.

Oncotarget. 2013 Jun;4(6):899-910.

16.

Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.

Zhao W, Gao Y, Bai B, Cai QC, Wang XX, Cai QQ, Huang HQ.

Expert Opin Drug Saf. 2015 Jan;14(1):21-9. doi: 10.1517/14740338.2015.988138. Epub 2014 Nov 21.

PMID:
25412839
17.

Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells.

Pichert G, Schmitz SF, Hess U, Cerny T, Cogliatti SB, Betticher D, Stupp R, Schmitter D, Stahel RA, Ghielmini M.

Clin Lymphoma. 2001 Mar;1(4):293-7.

PMID:
11707844
18.

Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.

Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B.

Oncol Rep. 2010 Oct;24(4):1101-7.

PMID:
20811695
19.

Follicular lymphoma: 2011 update on diagnosis and management.

Freedman A.

Am J Hematol. 2011 Sep;86(9):768-75. doi: 10.1002/ajh.22099. Review.

20.

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008079. doi: 10.1002/14651858.CD008079.pub2. Review.

PMID:
23152253

Supplemental Content

Support Center